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Introduction
Gastroesophageal variceal bleeding is a severe compli-
cation in cirrhotic patients. The vascular hyporespon-
siveness to vasoconstrictive agents during hemorrhage
also compromises hemostasis.1,2 Somatostatin and its
long-acting analog octreotide have been advocated to
control variceal hemorrhage with mechanisms not
fully elucidated.3,4 They seem to reduce splanchnic
blood flow mainly through the diminution of vasoac-
tive hormone release.5 Long-term octreotide treatment
has been found to ameliorate hyperdynamic circulation
and prevent in vitro mesenteric vascular hyporeactivity
in partially portal-vein-ligated (PVL) portal hypertensive
rats.6 In addition, it decreased portal pressure and
enhanced the constrictive response to vasopressin in
mesenteric arteries of PVL rats.7 Long-term octreotide
application also reduced portal pressure in cirrhotic
rats.8 However, the requirement of repeated injection
and subsequent desensitization9,10 hamper its clinical
utilization and therapeutic efficacy.
Endothelin-1 (ET-1), an endothelium-derived pep-
tide with protein kinase C-related vasoconstrictive prop-
erties,11 has been found to be increased in the liver 
of cirrhotic patients, and its level is proportional 
to the severity of liver disease.12 The decreased
metabolism and enhanced synthesis of ET-1 in hepa-
tocytes account for its elevated level in cirrhosis.13
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ET-1 induces intrahepatic and portosystemic collateral
vasoconstriction in cirrhotic rats and PVL rats.14–16
In addition, somatostatin and octreotide enhance 
ET-1-related portosystemic collateral vasoconstriction
if administered in the perfusate before ET-1 incuba-
tion.17 However, the effect of chronic somatostatin
analog administration on the collateral vascular ET-1
responsiveness in cirrhotic status is unknown.
Vasopressin controls gastroesophageal variceal hem-
orrhage mainly through splanchnic vasoconstriction
with decreased portal venous inflow and portal pres-
sure.18 Previous study indicated that vasopressin
decreased blood flow velocities of superior mesenteric
artery, portal vein, and esophageal varices.19 Further-
more, vasopressin exerts direct vasoconstrictive effect
on portosystemic collaterals of PVL rats.20 It has been
indicated that long-term octreotide administration
did not enhance the collateral vasoconstrictive effect
to vasopressin in PVL rats.21 However, whether or
not somatostatin analogs augment collateral vascular
responsiveness to vasopressin in cirrhosis deserves fur-
ther evaluation.
Considering the inconvenience of octreotide in
chronic treatment and the scarcity of information
regarding the actions of its related compounds on
collateral vascular responsiveness to vasoconstrictors,
this study used the in situ perfusion model to assess
the effect of lanreotide, a longer-acting somatostatin
analog when compared with octreotide,22 on the col-
lateral vascular reaction to ET-1 and arginine vaso-
pressin (AVP) in bile duct-ligated cirrhotic rats.
Methods
Animal model
Male Sprague–Dawley rats, weighing 240–270g at the
time of surgery, were used. They were housed in plastic
cages and allowed free access to food and water, and
then fasted for 12 hours before operation. Secondary
biliary cirrhosis was induced by common bile duct liga-
tion (BDL) with formalin infusion.23 Under ketamine
anesthesia (100mg/kg, intramuscularly), the common
bile duct was exposed through a midline abdominal
incision. It was catheterized by a PE-10 catheter and
doubly ligated with 3-0 silk. The first ligature was below
the junction of the hepatic ducts and the second was
above the entrance of the pancreatic duct. Ten percent
formalin (~100μL/100g) was slowly injected into the
biliary tree to prevent the subsequent dilatation of the
ligated residual bile duct. The PE-10 catheter was then
removed and the ligatures tightened, followed by sec-
tion of the common bile duct between the ligatures.
The incision was then closed and the animal was
allowed to recover. According to the literature, a high
yield of secondary biliary cirrhosis was noted 5 weeks
after BDL.23–25 To avoid coagulation defects, BDL
rats received vitamin K injection weekly (50 μg/kg,
intramuscularly).25 Perfusion studies were performed
6 weeks after BDL under ketamine anesthesia. Body
weights were measured on the day of perfusion studies.
The experiments adhered to the American Physiolog-
ical Society’s guiding principles for the care and use of
laboratory animals.
In situ perfusion preparation
The system was operated as previously described.16,20,26
Both jugular veins were cannulated with 16-gauge
Teflon cannulas to ensure an adequate outflow without
any resistance even at the highest flow rates. Heparin
(200 U/100 g body weight) was injected through one
of the cannulas. The abdomen was then opened and
an 18-gauge Teflon cannula was inserted in the distal
superior mesenteric vein and fixed with cyanoacrylate
glue. To exclude the liver from perfusion, a ligature
was tied around the portal vein. The animal was trans-
ferred into the upper compartment of a warm cham-
ber (37±0.5°C). The temperature around the perfusion
area was continuously monitored with a thermometer
inside the mesentery and maintained at 37±0.5°C with
a thermostatic pad and temperature-controlled infrared
lamp. An open circuit perfusion was then started with
Krebs solution (composition in mmol/L: NaCl, 118;
KCl, 4.7; KH2PO4, 1.2; MgSO4, 1.2; CaCl2, 2.5;
NaHCO3, 25; dextrose, 11.0; pH, 7.4; 37 ± 0.5°C)
via the mesenteric cannula by a roller pump (model
505S; Watson-Marlow Limited, Falmouth, Cornwall,
UK). The perfusate was equilibrated with carbogen
gas (95% O2–5% CO2) by a silastic membrane lung.27
Bilateral jugular vein cannulas were opened to allow a
complete washout of blood. Pneumothorax was cre-
ated by opening slits through the diaphragm to
increase pulmonary artery resistance and prevent the
perfusate from entering the left chambers of the
heart. The collaterals were then perfused with oxy-
genated (95% O2–5% CO2) Krebs solution containing
3% wt/vol albumin (factor V bovine serum albumin;
Sigma Chemical Co, St. Louis, MO, USA). The efflu-
ent of the perfused tissue was collected in a reservoir in
the lower compartment of the chamber and not recircu-
lated. To continuously monitor and record the collateral
pressure, a Spectramed DTX transducer (Spectramed
Inc., Oxnard, CA, USA) attached to a Gould model RS
3400 recorder (Gould Inc., Cupertino, CA, USA) was
connected to a side arm placed just proximal to the per-
fusion cannula, with the zero placed at the level of the
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right atrium. Because the temperature and pressure of
the system were stabilized within 20 minutes, all the
experiments were performed 25 minutes after starting
perfusion at a constant rate of 12mL/minute.16
Moreover, the perfusion flow rate was kept constant
throughout the whole experiment, so the perfusion
pressure changes reflected the collateral vascular resist-
ance changes. Only 1 concentration–response curve was
performed in each preparation. In each preparation,
after testing experimental agents, the contracting capa-
bility was challenged with a 125mmol/L potassium
chloride solution at the end of the experiments.
Measurement of systemic and 
portal hemodynamics
The right femoral artery and mesenteric vein were
cannulated with PE-50 catheters connected to a
Spectramed DTX transducer (Spectramed Inc.). Con-
tinuous recordings of mean arterial pressure, heart
rate, and portal pressure were performed on a multi-
channel recorder (model RS 3400, Gould Inc.). The
external zero reference was placed at the level of the
midportion of the rat.28,29
Experimental design
BDL rats randomly received lanreotide (10 mg/kg,
intramuscularly; Sandostatin® LAR®, Novartis, Basel,
Switzerland) or distilled water (control) once on the
33rd day after ligation. On the 43rd day after BDL, rats
underwent ketamine anesthesia, and then the body
weight, mean arterial pressure, portal pressure, and
heart rate were measured. Two series of experiments
with the in situ collateral perfusion model were per-
formed. In the first series (lanreotide, n = 6; control,
n = 7), cumulative concentration–response curves were
determined by graded final concentrations of ET-1
(10−10, 10−9, 3 × 10−9, 10−8, 3 × 10−8, 10−7 mol/L,
respectively) with a constant flow rate (12 mL/
minute).16 In the second series, the same procedure
was performed for another 2 groups of BDL rats 
(lanreotide, n=6; control, n=8) with 10−10, 10−9, 
3×10−9, 10−8, 3×10−8, 10−7, and 3×10−7 mol/L of
AVP, respectively. Each new concentration was allowed
to stabilize for 3 minutes before the next higher con-
centration was added. 
Drugs
Lanreotide (Sandostatin® LAR®) was purchased from
Norvatis Co. (Basel, Switzerland). The reagents for
preparing Krebs solution, ET-1, and AVP were pur-
chased from Sigma Chemical Co. All solutions were
freshly prepared on the days of the experiments.
Data analysis
All results are expressed as mean ± SEM. The changes
in perfusion pressure (mmHg) over baseline were cal-
culated for each concentration in each preparation.
Statistical analyses were performed using a 2-sample 
t test. Results were considered statistically significant
at a 2-tailed p value of less than 0.05.
Results
Hemodynamic effects of lanreotide
Table 1 shows the body weights and baseline hemo-
dynamic parameters of the different groups. They were
similar between the lanreotide and control groups.
Concentration–response relationships to ET-1
Figure 1 depicts the concentration–response curves
to various concentrations of ET-1 at a constant flow
rate. The maximal pressure changes occurred at 
10−7 mol/L. Compared with the control group, the lan-
reotide group had higher perfusion pressure changes,
which reached statistical significance at the ET-1 con-
centration of 10−7 mol/L (lanreotide vs. control: perfu-
sion pressure change, 25.2±1.4mmHg vs. 19.6±1.7
mmHg, p=0.032; percentage change: 182.8 ± 9.5% vs.
132.1±15.0%, p=0.019). The maximal pressure change
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Table 1. Body weight and baseline hemodynamics in the different experimental groups
n BW (g) MAP (mmHg) HR (beats/min) PP (mmHg) Baseline PP (mmHg)
ET-1 study
Lanreotide 6 367.7 ± 7.6 85.0 ± 7.4 257.0 ± 21.1 14.9 ± 1.5 13.8 ± 0.7
Control 7 349.3 ± 9.4 104.2 ± 5.3 278.1 ± 21.6 16.6 ± 1.3 13.6 ± 0.6
AVP study
Lanreotide 6 376.3 ± 20.3 92.3 ± 5.7 248.3 ± 13.8 14.7 ± 1.2 16.3 ± 0.8
Control 8 403.0 ± 16.5 94.9 ± 5.8 268.9 ± 19.8 16.6 ± 1.2 14.5 ± 1.6
p > 0.05 between lanreotide and control groups. BW = body weight; MAP = mean arterial pressure; HR = heart rate; PP = portal pressure; Baseline PP = base-
line perfusion pressure; ET-1 = endothelin-1; AVP = arginine vasopressin.
of the portosystemic collateral vessels challenged with
the 125mmol/L potassium chloride solution at the end
of experiments was 26.0±3.1mmHg for the lanreotide
group, which was not significantly different from the
control group (24.0±1.8mmHg, p=0.572).
Concentration–response relationships to AVP
Figure 2 depicts the concentration–response curves
to escalated concentrations of AVP. As compared with
the control group, the lanreotide group did not get
significantly different perfusion pressure changes to
AVP (p > 0.05). The maximal perfusion pressure
change occurred at the concentration of 3×10−8 mol/L
(lanreotide vs. control: 12.0 ± 1.9 mmHg vs. 11.9 ±
1.8 mmHg, p = 0.964; percentage change: 75.5 ±
12.6% vs. 82.1 ± 9.5%, p = 0.676). The maximal pres-
sure change of the portosystemic collateral vessels
challenged with the 125 mmol/L potassium chloride
solution at the end of experiments was 41.0 ± 4.2
mmHg for the lanreotide group, which was not 
significantly different from the control group (33.2 ±
3.1 mmHg, p = 0.153).
Discussion
Lanreotide, a somatostatin analog with a particular
ligand affinity for somatostatin receptor subtypes SSTR-2
and -5, has been developed and requires only weekly
injections.30 Continuous lanreotide infusion attenuates
postprandial splanchnic hyperemia in both normal sub-
jects31 and cirrhotic patients.32 In a previous study, no
diminishing effect of lanreotide was found over 8 hours
of constant food stimulation, i.e. no downregulation
or tachyphylaxis was observed.33 This distinct feature
makes long-term lanreotide administration possible
without significantly compromised efficacy. Since repet-
itive and short-term injections hinder the clinical feasi-
bility of somatostatin analogs, we surveyed the effect
of lanreotide on collateral vascular response with the
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Figure 1. Concentration–response curves to endothelin-1 (ET-1) in portosystemic collateral vascular beds of lanreotide and distilled-
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Figure 2. Concentration–response curves to arginine vasopressin (AVP) in portosystemic collateral vascular beds of lanreotide and 
distilled-water (control)-treated BDL rats, expressed as (A) absolute and (B) percentage increases over baseline value.
longest applicable duration from drug administration
to perfusion studies. According to Kuhn et al,30 plasma
lanreotide concentrations in healthy males remain
above 1.5 ng/mL until day 11. Therefore, we decided
to inject lanreotide on the 33rd day and performed
perfusion study on the 43rd day after BDL.
Lanreotide did not modify mean arterial pressure in
this study, consistent with the result of lanreotide injec-
tion once per week for 3 weeks in cirrhotic patients.34
The somatostatin-agonist-dependent desensitization
and internalization of the receptor SST235,36 was
ascribed to play a role in the attenuation in depot lan-
reotide’s hemodynamic efficacy. It has been found
that in portal hypertensive rats, a single intramuscular
injection of lanreotide 10 mg/kg immediately after
PVL did not induce significant changes in cardiac index
and systemic vascular resistance on the 8th day after
PVL, though significant alterations were noted on the
4th day.37 In patients with cirrhosis, octreotide 250 μg/
12 hr subcutaneously for 5 days exerted no significant
changes in systemic hemodynamics.38 In addition, an
immediate but short-acting influence of octreotide
on mean arterial pressure of cirrhotic patients was
observed,39,40 which lasted for only 5 minutes.40 There-
fore, somatostatin analogs do not induce sustained
systemic hemodynamic changes, both in portal hyper-
tensive and cirrhotic states.
The influence of somatostatin analogs on the por-
tal system is under debate. It has been demonstrated
that acute octreotide injection decreased portal tributary
blood flow and portal pressure in portal hypertensive
and cirrhotic rats.41 A similar finding was also found
in cirrhotic patients with acute treatment.42 However,
continuous infusion of octreotide in cirrhotic patients
failed to show such a beneficial effect.43 In a study with
intravenous bolus of octreotide followed by continu-
ous infusion in cirrhotic patients, portal venous flow
decreased compared to baseline at 1 minute but rap-
idly returned toward baseline, and by the 5th minute,
no significant difference was noted.39 Controversies
also exist in chronic treatment. In cirrhotic patients44
and rats,45 long-term octreotide administration exerts
a portal hypotensive effect, whereas the same finding
was not observed in rats with BDL or carbon tetra-
chloride-induced cirrhosis.46
Portal pressure was not altered by lanreotide in
the current study. In cirrhotic patients, lanreotide SR
30 mg once weekly for 3 weeks did not reduce base-
line and postprandial hepatic venous pressure gradient
or portal blood flow.34 However, these results are
inconsistent with those of a previous study, which
indicated that 1 lanreotide injection decreased portal
pressure and portal tributary blood flow in PVL
rats.37 The major cause of discrepancy may lie in the
different models, lanreotide application schedules and
timing of hemodynamic measurements. In the pre-
sent study, to simulate the clinical situation, lanreotide
was administered on the 33rd day after BDL, after the
initiation of hepatic injury and cirrhosis. In addition,
hemodynamic measurements were performed on the
10th day after lanreotide injection. However, in the
previous study,37 lanreotide was injected immediately
after PVL and hemodynamic changes were evaluated
on the 4th and 8th days after PVL, respectively. Fur-
thermore, collateral vascular response to ET-1 was
enhanced by lanreotide in the current study, which
may contribute to a higher portal pressure and offset
the potential portal hypotensive effect of lanreotide.
Apart from differences in duration and dosage of
octreotide treatment and the time of hemodynamic
survey, in cirrhotic rats receiving 1-week octreotide,
increased levels of serum 6-keto-PGF1a, nitrite/
nitrate, and enhanced aortic endothelial nitric oxide
synthase expression without correction of the hemo-
dynamic derangement were observed.47 Accentu-
ated endothelium-related vasodilatory activity after
octreotide treatment may overcome the octreotide-
induced hemodynamic effects in cirrhosis. Further-
more, it has been demonstrated that octreotide
caused a marked and transient decrease in portal pres-
sure and azygos blood flow and an increase in mean
arterial pressure in cirrhotic patients.40 These effects
lasted for only 5 minutes, despite addition of continu-
ous octreotide infusions. Repeated boluses even caused
tachyphylaxis. Resistance to octreotide by receptor
adaptation during 1-week octreotide administration
was also impressed.10,48 This rapid desensitization to
the effects of octreotide may explain its divergent
hemodynamic impacts in cirrhosis.
The effect of somatostatin analogs on variceal pres-
sure is still controversial, including a modest decrease49
or no modification.50 It has been noted that octreotide
decreased hepatic and azygos blood flows but exerted
only minimal effects on portal pressure.51,52 In addi-
tion, early and chronic administration of octreotide
prevented the development of portocollateral blood
flow without reducing portal pressure in 2 rat models
of cirrhosis.46 These observations suggest the possibility
of an increase in portal collateral resistance. Although
somatostatin and octreotide had no direct vasocon-
strictive effect on the collateral vessels of PVL rats, in
the presence of ET-1, somatostatin and octreotide
added in perfusate enhanced the ET-1-induced col-
lateral vasoconstriction.17 This is compatible with the
finding that in the presence of vasoconstrictors
involving activation of protein kinase C, such as ET-1,
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octreotide exerts a local vasoconstrictive effect on the
superior mesenteric artery.11 Similarly, potassium chlo-
ride (KCl)-induced vasoconstriction was not potenti-
ated by octreotide in the mesenteric vascular beds of
PVL rats.11 In the current study, a single injection of
lanreotide 10 days before perfusion study exerted
improved collateral vascular contraction response to
ET-1 at the concentration of 10−7 mol/L, whereas it
did not enhance the contractile response to KCl. In
parallel, octreotide administration for 7 days did not
change the collateral vascular responsiveness to KCl.21
Since ET-1 plays a pivotal role in the pathophysiology
of portal hypertension,53 the lack of a portal hypoten-
sive effect of lanreotide may be partially related to the
enhanced collateral vascular response to ET-1 by lan-
reotide. On the other hand, lanreotide did not induce
changes of collateral vascular responsiveness to AVP,
similar to a previous report on chronic octreotide
treatment.21 This might be attributed to the fact that
vasopressin does not act via protein kinase C.
In conclusion, a single injection of lanreotide, a
long-acting somatostatin analog, enhances portosys-
temic collateral vascular responsiveness to ET-1 in
BDL cirrhotic rats. However, it does not influence the
hyperdynamic circulation or the collateral reactiveness
to vasopressin.
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